Researcher use AI to predict Alzheimer's disease progression

Author

Kyle Wiggers

Published

February 2, 2019

Researchers at Unlearn.AI, a startup that designs software tools for clinical research, think that artificial intelligence has a valuable role to play in personalizing diagnosis and treatment.

Enter your email address to download paper.

Click the link to begin download.

Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.

Watch Now

Oops! Something went wrong while submitting the form.

Webinars

Applying Machine Learning to Increase Clinical Trial Efficiency: A Regulatory Journey

Press

Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials

Press

Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™

February 16, 2022

Collaborators will leverage AI-generated Digital Twins to enable smaller, more efficient pivotal clinical trials.

Watch now

April 19, 2022

Led by Insight Partners, financing builds on the company’s momentum in working with leading biopharmaceutical companies to improve clinical trial efficiency.

Watch Now

May 19, 2022

Learn about the evolution of ideas that led to our TwinRCT™ solution for smaller, more efficient clinical trials and recent EMA draft qualification opinion.

Watch Now

Researcher use AI to predict Alzheimer's disease progression

Enter your email address to download paper.

Enter your email address to watch the webinar.

Applying Machine Learning to Increase Clinical Trial Efficiency: A Regulatory Journey

Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials

Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™

Interested in a partnership?